CN104365942A - 一种桑葚清肝明目保健茶及其制备方法 - Google Patents
一种桑葚清肝明目保健茶及其制备方法 Download PDFInfo
- Publication number
- CN104365942A CN104365942A CN201410669094.1A CN201410669094A CN104365942A CN 104365942 A CN104365942 A CN 104365942A CN 201410669094 A CN201410669094 A CN 201410669094A CN 104365942 A CN104365942 A CN 104365942A
- Authority
- CN
- China
- Prior art keywords
- parts
- liver
- mulberries
- blood
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000008708 Morus alba Nutrition 0.000 title claims abstract description 112
- 238000002360 preparation method Methods 0.000 title claims description 18
- 210000004185 liver Anatomy 0.000 title abstract description 96
- 240000000249 Morus alba Species 0.000 title abstract description 44
- 230000004438 eyesight Effects 0.000 title abstract description 16
- 244000269722 Thea sinensis Species 0.000 title abstract 4
- 241000218231 Moraceae Species 0.000 claims abstract description 71
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 51
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 230000003071 parasitic effect Effects 0.000 claims abstract description 20
- 240000001432 Calendula officinalis Species 0.000 claims abstract description 19
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 18
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 18
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 18
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 18
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 18
- 244000197580 Poria cocos Species 0.000 claims abstract description 18
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 18
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 18
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 244000112814 pipewort Species 0.000 claims abstract description 15
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 14
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 14
- 241000488974 Loranthus Species 0.000 claims abstract description 14
- 240000006688 Telosma cordata Species 0.000 claims abstract description 14
- 235000017352 Telosma cordata Nutrition 0.000 claims abstract description 14
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 241001122767 Theaceae Species 0.000 claims description 35
- 230000008901 benefit Effects 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- 238000010438 heat treatment Methods 0.000 claims description 19
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 17
- 240000007164 Salvia officinalis Species 0.000 claims description 15
- 230000036541 health Effects 0.000 claims description 15
- 235000005412 red sage Nutrition 0.000 claims description 15
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 13
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 13
- 241000218989 Trichosanthes Species 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 235000003373 curcuma longa Nutrition 0.000 claims description 13
- 235000013976 turmeric Nutrition 0.000 claims description 13
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 12
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 8
- 238000005202 decontamination Methods 0.000 claims description 7
- 230000003588 decontaminative effect Effects 0.000 claims description 7
- 230000004345 fruit ripening Effects 0.000 claims description 7
- 235000012907 honey Nutrition 0.000 claims description 7
- 238000010025 steaming Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 230000008030 elimination Effects 0.000 claims description 4
- 238000003379 elimination reaction Methods 0.000 claims description 4
- 235000011837 pasties Nutrition 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000005057 refrigeration Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 244000163122 Curcuma domestica Species 0.000 claims 3
- 244000170916 Paeonia officinalis Species 0.000 claims 3
- 239000008280 blood Substances 0.000 abstract description 92
- 210000004369 blood Anatomy 0.000 abstract description 82
- 230000000694 effects Effects 0.000 abstract description 54
- 210000001508 eye Anatomy 0.000 abstract description 47
- 208000002193 Pain Diseases 0.000 abstract description 22
- 230000036407 pain Effects 0.000 abstract description 22
- 230000007812 deficiency Effects 0.000 abstract description 19
- 230000035922 thirst Effects 0.000 abstract description 14
- 235000019640 taste Nutrition 0.000 abstract description 13
- 208000002173 dizziness Diseases 0.000 abstract description 12
- 230000006870 function Effects 0.000 abstract description 12
- 210000003734 kidney Anatomy 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 8
- 208000009205 Tinnitus Diseases 0.000 abstract description 8
- 230000036039 immunity Effects 0.000 abstract description 8
- 206010022437 insomnia Diseases 0.000 abstract description 8
- 231100000886 tinnitus Toxicity 0.000 abstract description 8
- 210000003127 knee Anatomy 0.000 abstract description 7
- 206010022998 Irritability Diseases 0.000 abstract description 6
- 206010033557 Palpitations Diseases 0.000 abstract description 3
- 230000008961 swelling Effects 0.000 abstract description 3
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 206010013774 Dry eye Diseases 0.000 abstract 2
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 abstract 1
- 235000003880 Calendula Nutrition 0.000 abstract 1
- 240000006766 Cornus mas Species 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000001050 lubricating effect Effects 0.000 abstract 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000002028 premature Effects 0.000 abstract 1
- 239000008517 radix Trichosanthis Substances 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000009978 visual deterioration Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 206010023126 Jaundice Diseases 0.000 description 13
- 235000019197 fats Nutrition 0.000 description 13
- 238000010791 quenching Methods 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 244000008991 Curcuma longa Species 0.000 description 10
- 241000736199 Paeonia Species 0.000 description 10
- 210000001124 body fluid Anatomy 0.000 description 10
- 239000010839 body fluid Substances 0.000 description 10
- 235000009508 confectionery Nutrition 0.000 description 10
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000036770 blood supply Effects 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 206010049865 Achromotrichia acquired Diseases 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 7
- 230000003796 beauty Effects 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 238000005728 strengthening Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102000002045 Endothelin Human genes 0.000 description 6
- 108050009340 Endothelin Proteins 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 6
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 240000008866 Ziziphus nummularia Species 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 6
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 6
- 229960004844 lovastatin Drugs 0.000 description 6
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 6
- 235000011090 malic acid Nutrition 0.000 description 6
- 239000001630 malic acid Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 231100000862 numbness Toxicity 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- 235000014101 wine Nutrition 0.000 description 6
- -1 0.27 milligram Chemical compound 0.000 description 5
- 208000037093 Menstruation Disturbances Diseases 0.000 description 5
- 206010027339 Menstruation irregular Diseases 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 206010047513 Vision blurred Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 231100000397 ulcer Toxicity 0.000 description 5
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 4
- 206010002368 Anger Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 239000001263 FEMA 3042 Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 4
- 244000061176 Nicotiana tabacum Species 0.000 description 4
- 239000005642 Oleic acid Substances 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- 208000034189 Sclerosis Diseases 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 231100000012 chronic liver injury Toxicity 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 210000000867 larynx Anatomy 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000002633 protecting effect Effects 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- 235000015523 tannic acid Nutrition 0.000 description 4
- 229940033123 tannic acid Drugs 0.000 description 4
- 229920002258 tannic acid Polymers 0.000 description 4
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241000475481 Nebula Species 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 206010047571 Visual impairment Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002279 cholagogic effect Effects 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 208000029257 vision disease Diseases 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 240000000111 Saccharum officinarum Species 0.000 description 2
- 235000007201 Saccharum officinarum Nutrition 0.000 description 2
- 241000447727 Scabies Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000002605 anti-dotal effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000003464 asthenopia Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000035568 catharsis Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 239000003176 neuroleptic agent Substances 0.000 description 2
- 230000000701 neuroleptic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 235000021313 oleic acid Nutrition 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 208000005687 scabies Diseases 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 235000015096 spirit Nutrition 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- ABTRFGSPYXCGMR-KXQOOQHDSA-N (3R)-beta,psi-caroten-3-ol Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C ABTRFGSPYXCGMR-KXQOOQHDSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 244000252230 Artemisia stelleriana Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 235000016811 Biondella Nutrition 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- FEPOUSPSESUQPD-UHFFFAOYSA-N Cymbopogon Natural products C1CC2(C)C(C)C(=O)CCC2C2(C)C1C1(C)CCC3(C)CCC(C)C(C)C3C1(C)CC2 FEPOUSPSESUQPD-UHFFFAOYSA-N 0.000 description 1
- 241000931332 Cymbopogon Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 241000300213 Eriocaulon buergerianum Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 241000427324 Glinus Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000538804 Lethrinus haematopterus Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241000221040 Loranthaceae Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 244000292697 Polygonum aviculare Species 0.000 description 1
- 235000006386 Polygonum aviculare Nutrition 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241000951473 Schizonepeta Species 0.000 description 1
- 241000316332 Scurrula Species 0.000 description 1
- 240000001638 Scurrula parasitica Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 241001530209 Swertia Species 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 1
- 235000008611 Viola japonica Nutrition 0.000 description 1
- 244000136184 Viola japonica Species 0.000 description 1
- 244000137773 Viola philippica Species 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000055320 Viscum coloratum Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000035603 choleresis Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 239000000242 nostrum Substances 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000009514 rubixanthin Nutrition 0.000 description 1
- 239000000455 rubixanthin Substances 0.000 description 1
- ABTRFGSPYXCGMR-SDPRXREBSA-N rubixanthin Natural products O[C@H]1CC(C)(C)C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=C(\CC/C=C(\C)/C)/C)\C)/C)\C)/C)=C(C)C1 ABTRFGSPYXCGMR-SDPRXREBSA-N 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000005982 spleen dysfunction Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 230000001551 toxigenic effect Effects 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000019245 violaxanthin Nutrition 0.000 description 1
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种桑葚清肝明目保健茶,所述桑葚清肝明目保健茶中各种原料的重量份数为:桑葚10~50份,女贞子10~20份,谷精草10~20份,郁金10~20份,丹参10~20份,茯苓10~20份,金盏花10~20份,茵陈10~20份,天花粉10~20份,桑寄生10~20份,白芍10~20份,栀子10~20份,虎杖10~20份,紫花地丁10~20份,山茱萸10~20份。桑椹味酸,性微寒,具有提高人体免疫力、补血滋阴、生津止渴、润肠祛燥等功效,主治阴血不足而致的头晕目眩、耳鸣心悸、烦躁失眠、腰膝酸软、须发早白、消渴止干、大便干结、滋阴补血、安神补脑、等功效。再加上一些滋肝补肾、清肝明目,口感清淡的中药,共同作用,对肝阴亏损,两目干涩、视力减退;肝火上炎,目赤肿痛;对用眼过度造成眼睛发干发涩有良好的保健作用。
Description
技术领域
本发明涉及含有来源于植物组份的保健品,特别涉及一种桑葚清肝明目保健茶及其制备方法。
背景技术
经常玩电脑游戏、手机游戏成了许多人生活的习惯,有的人能一动不动打一天游戏。长期久坐用眼,除双目供血不足外,颈椎、腰椎也会产生劳损,总得不到缓解,也会对肝脏造成损害。中医认为肝主目:“肝气通于目,肝和则目能辨五色矣”。肝的病变往往影响及眼睛,这个心灵的窗户。现代都市上班族普遍使用电脑办公,再加上烟酒无度,夜生活不节制,熬夜,这些都直接伤害了肝气。如肝血不足,则两目干涩,视物不清或夜盲;肝经风热,可见目赤痒痛;肝火上炎,可见目赤生翳;肝阳上亢,则头目眩晕;肝风内动,可见目斜上视等。
《黄帝内经》的“五劳所伤”中有一伤:“久视伤血“。这里的血,指的就是肝血。眼睛与肝脏联系紧密。肝藏血,即肝脏具有贮藏血液和调节血量的功能,而且肝开窍于目。双眼受到血的给养才能视物,而过度用眼,会使肝血亏虚,使双目得不到营养的供给,从而出现眼干涩、看东西模糊、夜盲等。另外,长期久坐用眼打游戏,除双目供血不足外,颈椎、腰椎也会产生劳损,总得不到缓解,也会对肝脏造成损害。这种情况下,出现双眼疲劳、视力下降,甚至面色萎黄,头晕眼花的症状,也就不奇怪了。久视以及辐射,为电脑一族的眼睛健康埋下了隐患。
肝主疏泄,泛指肝气具有疏通、条达、升发、畅泄等综合生理功能。古人以木气的冲和条达之象来类比肝的疏泄功能,故在五行中将其归属于木,故《素问·灵兰秘典论》说:“肝者,将军之官,谋虑出焉”,《素问·六节脏象论》说:“肝者,罢极之本,魂之居也”。肝主疏泄的功能主要表现在调节精神情志,促进消化吸收,以及维持气血、津液的运行三方面。
桑葚为桑科落叶乔木桑树的成熟果实,桑葚又叫桑果、桑枣,农人喜欢其成熟的鲜果食用,味甜汁多,是人们常食的水果之一。中医学认为桑椹补益肝肾,滋阴养血,息风,具有主治心悸失眠、头晕目眩、耳鸣、便秘盗汗、瘰疬、关节不利等病症。成熟的桑葚质油润,酸甜适口,以个大、肉厚、色紫红、糖分足者为佳。每年4~6月果实成熟时采收,洗净,去杂质,晒干或略蒸后晒干食用。
在两千多年前,桑葚已是中国皇帝御用的补品。因桑树特殊的生长环境使桑果具有天然生长、无任何污染的特点,所以桑葚又被称为“民间圣果”。现代研究证实,桑葚果实中含有丰富的活性蛋白、维生素、氨基酸、胡萝卜素、矿物质、白藜芦醇、花青素等成份,营养是苹果的5~6倍,是葡萄的4倍,具有多种功效,被医学界誉为“二十一世纪的最佳保健果品”。常吃桑葚能显著提高人体免疫力,具有延缓衰老,美容养颜的功效。
中国传统医学认为桑椹味酸,性微寒,具有提高人体免疫力、补血滋阴、生津止渴、润肠祛燥等功效,主治阴血不足而致的头晕目眩、耳鸣心悸、烦躁失眠、腰膝酸软、须发早白、消渴止干、大便干结、滋阴补血、安神补脑、利关节、去风湿、解酒等功效。
1、防止血管硬化:桑椹中含有脂肪酸,主要由亚油酸。硬脂酸及油酸组成,具有分解脂肪,降低血脂,防止血管硬化等作用。
2、健脾胃,助消化:桑椹中含有鞣酸、脂肪酸、苹果酸等营养物质,能帮助脂肪、蛋白质及淀粉的消化,故有健脾胃助消化之功,可用于治疗因消化不良而导致的腹泻。
3、补充营养:桑椹中含有大量的水分、碳水化合物、多种维生素、胡萝卜素及人体必需的微量元素等,能有效地扩充人体的血容量,且补而不腻,适宜于高血压、妇女病患者食疗。
4、乌发美容:桑椹中含有大量人体所需要的营养物质,还含有乌发素,能使头发变得黑而亮泽,可用来美容。
桑椹,又名桑椹子、桑蔗、桑枣、桑果、乌椹等,为桑科植物桑的果穗。桑椹嫩时色青,味酸,老熟时色紫黑,多汁,味甜。成熟的桑椹果营养丰富,每100克桑椹含水分81.8克,蛋白质1.8克,脂肪0.3克。纤维素4.9克,碳水化合物10克,灰分1.2克,胡萝卜素30微克,硫胺素0.02毫克、核黄素0.06毫克,维生素E6.95毫克,钾33毫克,锌0.27毫克,铜0.08毫克,硒4.8微克。此外,还含有鞣酸,苹果酸,维生素C和脂肪酸等。其脂肪主要为亚油酸、油酸、软脂酸、硬脂酸和少量辛酸、壬酸、癸酸、肉豆蔻酸、亚麻酸等。
桑葚有改善皮肤(包括头皮)血液供应,营养肌肤,使皮肤白嫩及乌发等作用,并能延缓衰老。桑葚是中老年人健体美颜、抗衰老的佳果与良药。常食桑椹可以明目,缓解眼睛疲劳干涩的症状。桑葚具有免疫促进作用。桑葚对脾脏有增重作用,对溶血性反应有增强作用,可防止人体动脉硬化、骨骼关节硬化,促进新陈代谢。它可以促进血红细胞的生长,防止白细胞减少,并对治疗糖尿病、贫血、高血压、高血脂、冠心病、神经衰弱等病症具有辅助功效。桑椹具有生津止渴、促进消化、帮助排便等作用,适量食用能促进胃液分泌,刺激肠蠕动及解除燥热。祖国医学认为,桑葚性味甘寒,具有补肝益肾、生津润肠、乌发明目等功效。
现在市面上各种养肝护肝保健品、药品泛滥,但大多数徒有其表,大张旗鼓的虚假宣传,很可能没有任何保健功能,但造成人身体的巨大伤害,因此,寻找健康有效的保肝护肝的保健品具有很现实的重要意义。中药保肝护肝具有无毒、能被生物体完全吸收的优点,是我们研究的主要方向。另外,长期久坐用眼,除双目供血不足外,颈椎、腰椎也会产生劳损,总得不到缓解,也会对肝脏造成损害。如果单纯靠药物治疗恐怕很难坚持,胡乱使用眼药水更会使眼睛受损伤,导致各种眼病或失明的危险,且服用中药比较麻烦,口感不佳,不宜长期服用,效果也不一定理想。
发明内容
本发明所要解决的技术问题在于,现代人工作压力大,环境污染严重,烟酒无度,夜生活不节制,爱玩电脑手机游戏;长期久坐用眼,除双目供血不足外,颈椎、腰椎也会产生劳损,总得不到缓解,也会对肝脏造成损害。现在市面上各种养肝护肝保健品、药品泛滥,但大多数徒有其表,大张旗鼓的虚假宣传,很可能没有任何保健功能,但造成人身体的巨大伤害。本发明其味甘甜,清香四溢;没有中药的清苦气息;让人易于接受;再加上一些滋补肝肾,口感平和使人易于接受的中药,能较好的达到滋补肝肾、益阴养血、补虚益精气,祛风明目,滋补肝肾的功效,对慢性肝炎、脂肪肝、酒精肝和药物性肝损害等各种肝脏疾病的治疗有很高的保健作用,针对性更强。
为解决上述技术难题,本发明提供一种桑葚清肝明目保健茶,其所述桑葚清肝明目保健茶中各种原料的重量份数可以为:桑葚10~50份,女贞子10~20份,谷精草10~20份,郁金10~20份,丹参10~20份,茯苓10~20份,金盏花10~20份,茵陈10~20份,天花粉10~20份,桑寄生10~20份,白芍10~20份,栀子10~20份,虎杖10~20份,紫花地丁10~20份,山茱萸10~20份。
所述桑葚清肝明目保健茶,其所述桑葚清肝明目保健茶中各种原料的重量份数还可以为:桑葚10~30份,女贞子10~15份,谷精草10~15份,郁金10~15份,丹参10~15份,茯苓10~15份,金盏花10~15份,茵陈10~15份,天花粉10~20份,桑寄生10~20份,白芍10~20份,栀子10~20份,虎杖10~20份,紫花地丁10~20份,山茱萸10~20份。
所述桑葚清肝明目保健茶,其所述桑葚清肝明目保健茶中各种原料的重量份数也可以为:桑葚10~40份,女贞子10~20份,谷精草10~20份,郁金10~20份,丹参10~20份,茯苓10~20份,金盏花10~20份,茵陈10~20份,天花粉10~15份,桑寄生10~15份,白芍10~15份,栀子10~15份,虎杖10~15份,紫花地丁10~15份,山茱萸10~15份。
为解决上述技术问题,本发明还提供一种桑葚清肝明目保健茶的制备方法,其所述桑葚清肝明目保健茶的制备步骤包括以下方面:
a.桑葚的制备;
b.将所述其他原料粉碎、浸泡、加热、回流提取2次;
c.再将其他原料提取的药液放入浓缩器中浓缩;加蜂蜜或糊精制成颗粒剂、粉剂或膏剂;
d.将浓缩的颗粒剂、粉剂或膏剂与制备好的桑葚混合,制备成保健茶。
所述步骤a中,可以再每年4~6月桑葚果实成熟时采收,洗净,去杂质,晒干或略蒸后晒干。
所述步骤b中,可以取其他原料洗净晾干,用粉碎机粉碎过80-100目筛;将过筛的颗粒物浸泡水中12小时,然后放入提取罐加热煮沸1小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸半小时,过滤,加热浓缩至膏状,静置备用。
所述步骤c中,可以将膏状提取物置于70-90%乙醇中浸泡1-2小时,在水浴锅内加热到60℃-70℃,浸提2h,每10min搅拌一次,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状滤液,再置入双效真空浓缩器中,浓缩后的膏剂加蜂蜜调和制成颗粒剂;或直接干燥制成粉剂。
所述步骤d中,可以将制好的桑葚与提取的颗粒剂、粉剂或膏剂混合,经紫外线消毒杀菌后装袋,使用时直接冲水泡饮。
为解决上述技术问题,本发明再提供一种桑葚清肝明目保健茶的制备方法,所述保健茶的其他原料制成膏剂时步骤还可以为:
a、取其他原料放入乙醇中浸泡,热提取2次;
b、将提取液放置于浓缩器中浓缩成膏剂。
所述步骤a中,可以取其他原料洗净去杂,泡入乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液;所述步骤b中,可以将上述步骤提取的提取液放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06的浓缩液;将上述步骤得到的浸膏置入双效真空浓缩器中,浓缩至90℃时相对密度为1.50的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量;浓缩成的膏剂。
本发明有益的技术效果在于,桑椹味酸,性微寒,具有提高人体免疫力、补血滋阴、生津止渴、润肠祛燥等功效,主治阴血不足而致的头晕目眩、耳鸣心悸、烦躁失眠、腰膝酸软、须发早白、消渴止干、大便干结、滋阴补血、安神补脑、等功效。再加上一些滋肝补肾、清肝明目,口感清淡的中药,共同作用,对肝阴亏损,两目干涩、视力减退;肝火上炎,目赤肿痛;对用眼过度造成眼睛发干发涩有良好的保健作用。
具体实施方式
肝开窍于目,目的视觉功能主要依赖肝之阴血的濡养;肝的经脉又上联目系。因此,肝的功能正常与否常常在目上反映出来。例如:肝血不足可出现视物模糊、夜盲;肝阴亏损,则两目干涩、视力减退;肝火上炎,则目赤肿痛。中医强调,人要经常疏肝气、清肝毒、降肝火、养肝血,疏肝气可使全身气机疏泄通畅,体内不堵则面上无痘;清肝毒可化解消除体内污染,体内无毒则脸无暗色;降肝火可使体内阴阳平衡,体内不焦则皮肤滋润不燥;养肝血可以滋养全身脏器,肝血充盈则体表光泽有弹性。修复受损肝脏,使全身气机疏泄条达,全身气血顺畅运行,以达到疏肝养颜目的。产生毒素的源头是肝。当肝不能很好地完成解毒工作时,毒素就在体内漫延。疏肝养颜首先从肝脏健康入手,让健康的肝脏完成各项解毒工作,彻底切断毒素来源,让容颜持久美丽。
中医认为肝主目:“肝气通于目,肝和则目能辨五色矣”。肝的病变往往影响及眼睛,这个心灵的窗户。现代都市上班族普遍使用电脑办公,再加上烟酒无度,夜生活不节制,熬夜,这些都直接伤害了肝气。如肝血不足,则两目干涩,视物不清或夜盲;肝经风热,可见目赤痒痛;肝火上炎,可见目赤生翳;肝阳上亢,则头目眩晕;肝风内动,可见目斜上视等。
《黄帝内经》的“五劳所伤”中有一伤:“久视伤血“。这里的血,指的就是肝血。眼睛与肝脏联系紧密。肝藏血,即肝脏具有贮藏血液和调节血量的功能,而且肝开窍于目。双眼受到血的给养才能视物,而过度用眼,会使肝血亏虚,使双目得不到营养的供给,从而出现眼干涩、看东西模糊、夜盲等。另外,长期久坐用眼,除双目供血不足外,颈椎、腰椎也会产生劳损,总得不到缓解,也会对肝脏造成损害。这种情况下,出现双眼疲劳、视力下降,甚至面色萎黄,头晕眼花的症状,也就不奇怪了。久视以及辐射,为电脑一族的眼睛健康埋下了隐患。
中国传统医学认为桑椹味酸,性微寒,具有提高人体免疫力、补血滋阴、生津止渴、润肠祛燥等功效,主治阴血不足而致的头晕目眩、耳鸣心悸、烦躁失眠、腰膝酸软、须发早白、消渴止干、大便干结、滋阴补血、安神补脑、利关节、去风湿、解酒等功效。
1、防止血管硬化:桑椹中含有脂肪酸,主要由亚油酸。硬脂酸及油酸组成,具有分解脂肪,降低血脂,防止血管硬化等作用。
2、健脾胃,助消化:桑椹中含有鞣酸、脂肪酸、苹果酸等营养物质,能帮助脂肪、蛋白质及淀粉的消化,故有健脾胃助消化之功,可用于治疗因消化不良而导致的腹泻。
3、补充营养:桑椹中含有大量的水分、碳水化合物、多种维生素、胡萝卜素及人体必需的微量元素等,能有效地扩充人体的血容量,且补而不腻,适宜于高血压、妇女病患者食疗。
4、乌发美容:桑椹中含有大量人体所需要的营养物质,还含有乌发素,能使头发变得黑而亮泽,可用来美容。
桑椹,又名桑椹子、桑蔗、桑枣、桑果、乌椹等,为桑科植物桑的果穗。桑椹嫩时色青,味酸,老熟时色紫黑,多汁,味甜。成熟的桑椹果营养丰富,每100克桑椹含水分81.8克,蛋白质1.8克,脂肪0.3克。纤维素4.9克,碳水化合物10克,灰分1.2克,胡萝卜素30微克,硫胺素0.02毫克、核黄素0.06毫克,维生素E6.95毫克,钾33毫克,锌0.27毫克,铜0.08毫克,硒4.8微克。此外,还含有鞣酸,苹果酸,维生素C和脂肪酸等。其脂肪主要为亚油酸、油酸、软脂酸、硬脂酸和少量辛酸、壬酸、癸酸、肉豆蔻酸、亚麻酸等。
桑葚有改善皮肤(包括头皮)血液供应,营养肌肤,使皮肤白嫩及乌发等作用,并能延缓衰老。桑葚是中老年人健体美颜、抗衰老的佳果与良药。常食桑椹可以明目,缓解眼睛疲劳干涩的症状。桑葚具有免疫促进作用。桑葚对脾脏有增重作用,对溶血性反应有增强作用,可防止人体动脉硬化、骨骼关节硬化,促进新陈代谢。它可以促进血红细胞的生长,防止白细胞减少,并对治疗糖尿病、贫血、高血压、高血脂、冠心病、神经衰弱等病症具有辅助功效。桑椹具有生津止渴、促进消化、帮助排便等作用,适量食用能促进胃液分泌,刺激肠蠕动及解除燥热。桑葚性味甘寒,具有补肝益肾、生津润肠、乌发明目等功效。
丹参苦,微寒。归心、肝经。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠。用于胸肋胁痛,风湿痹痛,症瘕结块,疮疡肿痛,跌仆伤痛,月经不调,经闭痛经,产后瘀痛等。治疗胸肋疼痛、症瘕结块,以及月经不调、经闭经痛具有良效。《纲目》载:丹参,按《妇人明理论》云,四物汤治妇人病,不问产前产后,经水多少,皆可通用,惟一味丹参散,主治与之相同。盖丹参能破宿血,补新血,安生胎,落死胎,止崩中滞下,调经脉。丹参主要成分丹参酮有扩张血管、改善循环、解除血管内凝血等作用,具有活血化痕之功效,并能促进肝脏血液循环,利于肝细胞再生。
茯苓味甘、淡、性平,入药具有利水渗湿、益脾和胃、宁心安神之功用。现代医学研究:茯苓能增强机体免疫功能,茯苓多糖有明显的抗肿瘤及保肝脏作用。茯苓性味甘淡平,入心、肺、脾经。具有渗湿利水,健脾和胃,宁心安神的功效。可治小便不利,水肿胀满,痰饮咳逆,呕逆,恶阻,泄泻,遗精,淋浊,惊悸,健忘等症。茯苓之利水,是通过健运脾肺功能而达到的,与其它直接利水的中药不同。用于脾虚泄泻,带下茯苓既能健脾,又能渗湿,对于脾虚运化失常所致泄泻、带下,应用茯苓有标本兼顾之效,常与党参、白芍、山药等配伍。有可用为补肺脾,治气虚之辅佐药。
天花粉为葫芦科植物栝蒌的根,是一种中药,为清热泻火类药物,其具体功效是清热泻火,生津止渴,排脓消肿。主治:治热病口渴、消渴、黄疸、肺燥咳血、痈肿、痔痿。对于治疗糖尿病,常用它与滋阴药配合使用,以达到标本兼治的作用。《本草汇言》:天花粉,退五脏郁热,如心火盛而舌干口燥,肺火盛而咽肿喉痹,脾火盛而口舌齿肿,痰火盛而咳嗽不宁。若肝火之胁胀走注,肾火之骨蒸烦热,或痈疽已溃未溃,而热毒不散,或五疸身目俱黄,而小水若淋若涩,是皆火热郁结所致,惟此剂能开郁结,降痰火,并能治之。又其性甘寒,善能治渴,从补药而治虚渴,从凉药而治火渴,从气药而治郁渴,从血药而治烦渴,乃治渴之要药也。
山茱萸,主治心下邪气寒热,温中,逐寒温痹,去三虫,久服轻身有强阴益精、安五脏、通九窍、止小便淋沥之功;久服明目、强力长年。山茱萸,又名山芋肉、药枣、实枣儿、枣皮、肉枣等,为我国常用名贵中药材,应用历史悠久。它以其补力平和、壮阳而不助火,滋阴而不腻膈,收敛而不留邪等特殊功效被历代医学所喜用。张仲景以山茱萸为君创制了“金匮肾气丸”。据化学分析,山茱萸含有生理活性较强的山茱萸甙、酒石酸、没食子酸、苹果酸、树酯、鞣质和多种维生素等有效成分,具有增强免疫、抗炎、抗菌等药理作用,是中医临床中常用的一味药。
茵陈性微寒,味辛、苦功能主治清湿热,退黄疸。用于黄疸尿少、湿疮瘙痒、传染性黄疸型肝炎。茵陈的功效。清热利湿;退黄.主治:黄疸;小便不利;湿疮瘙痒等.药理学研究有利胆,保护肝功能,解热,抗炎,降血脂,降压,扩冠等作用,当然,这只是西医学提取茵陈成分做出来的研究,临床应用上效果如何不好判定。茵陈用量过大可引起头晕,恶心,腹泻,上腹部不适,急性肝胆损伤,亦有心律不齐的报导.但是治疗剂量的茵陈一般不会造成严重的损伤。茵陈有显著的保肝作用,对甲,乙型肝炎,黄疸型肝炎,有显著的疗效.有利胆,促进胆汁分泌,增加胆汁中胆酸和胆红素排出的作用.能增加心脏冠脉血流量,改善微循环,并有降血压,降血脂,抗凝血,利尿解热平喘,驱除蛔虫及抑制多种致病性皮肤真菌与细菌的作用。
郁金辛、苦,寒。归肝、心、肺经。功能主治行气化瘀,清心解郁,利胆退黄。用于经闭痛经,胸腹胀痛、刺痛,热病神昏,癫痫发狂,黄疸尿赤。行气解郁,凉血破瘀。治胸腹胁肋诸痛,失心癫狂,热病神昏,吐血,衄血,尿血,血淋,妇女倒经,黄疸。《药性论》载其:治女人宿血气心痛,冷气结聚,温醋摩服之。《唐本草》载其:主血积,下气,生肌,止血,破恶血,血淋,尿血,金疮。
金盏花学名:Cymbopogon citrat,金盏花也名金盏菊,其性味淡平,花、叶有消炎、抗菌作用。根能行气活血,花可凉血、止血。欧洲民间早就外用在皮肤、粘膜的各种炎症上,也可内服治疗各种炎症及溃疡。金盏菊富含多种维生素,尤其是维生素A和维生素C;几乎各部位都可以食用;其花瓣有美容之功能,花含类胡萝卜素、番茄烃、蝴蝶梅黄素、玉红黄质、挥发油、树脂、黏液质、苹果酸等。根含苦味质,山金东二醇;种子含甘油酯、蜡醇和生物碱。放入洗发精里可以使得头发颜色变淡。金盏菊性味淡平,花、叶有消炎、抗菌作用。根能行气活血,花可凉血、止血。欧洲民间外用于皮肤、粘膜的各种炎症,也可以内服治疗各种炎症及溃疡。新鲜的花卉可以放在色拉里吃。金盏花富含黄酮类活性成分,该成分具有抗氧化、抗血管增生、消炎、抗变应性、和抗病毒的功效,通过issofree技术可对金盏花活性成分进行提取并应用于抗敏感类高端护肤品。
白芍入肝、脾经,养血柔肝,缓中止痛,敛阴收汗。治胸腹胁肋疼痛,泻痢腹痛,自汗盗汗,阴虚发热,月经不调,崩漏,带下,妇人血闭不通,消瘀血,能蚀脓,益女子血。《日华子本草》:治风、补劳,主女人一切病,并产前后诸疾,通月水,退热,除烦,益气,天行热疾,瘟瘴,惊狂,妇人血运,及肠风,泻血,痔瘘。发背,疮疥,头痛,明目,目赤努肉。赤色者多补气,白者治血。
桑寄生为桑寄生科常绿小灌木植物桑寄生Loranthusparasiticus(L.)Merr.或槲寄生Viscumcoloratum(Komar.)Nakai的带叶茎枝。又名桃树寄生《圣惠方》,苦楝寄生《本草求原》,广寄生《中药志》,相思树寄生、槐花寄生《广西药用植物名录》,梧州寄生茶《实用中草药彩色图集》,寄生茶(广西),松树寄生(海南)。有祛风湿,益肝肾,强筋骨,安胎的功效。补肝肾;强筋骨;祛风湿;安胎。主腰膝酸痛;筋骨痿弱;肢体偏枯;风湿痹痛;头错目眩;胎动不安,崩漏下血。用于风湿痹痛,腰膝酸软,筋骨无力,崩漏经多,妊娠漏血,胎动不安;高血压。
女贞子用于肝肾阴虚的目暗不明,视力减退,须发早白,腰酸耳鸣及阴虚发热等。本品能补肝肾阴,但药力平和,须缓慢取效。治目暗不明,常配熟地,郁金等同用,治须发早白,常配桑葚同用,阴虚发热,常配地骨皮。肝肾阴虚,头昏目眩、遗精耳鸣、腰膝酸软,须发早白,冠心病、高脂血症、高血压、慢性肝炎。对肝脏的保护作用研究认为,女贞子含有齐墩果酸,给大鼠皮下注射,可降低血清谷丙转氨酶,对四氯化碳诱发的肝损伤有明显保护作用,并能促进肝细胞再生.齐墩果酸亦可使肝内甘油三酯蓄积减少、肝细胞变性坏死明显减轻、糖原蓄积增加、血清γ球蛋白下降;超微结构可见肝细胞内线粒体肿胀与内质网囊泡变性减轻、肝组织间质炎症反应减弱。
栀子是传统中药,属卫生部颁布的第1批药食两用资源,具有护肝、利胆、降压、镇静、止血、消肿等作用,在中医临床常用于治疗黄疸型肝炎、扭挫伤、高血压、糖尿病等症。主治热病心烦;肝火目赤;头痛;湿热黄疸;淋证;血痢尿血;口舌生疮;疮疡肿毒;扭伤肿痛。本品对目赤肿痛有很大疗效。该品清泻三焦热邪,可治肝胆火热上攻之目赤肿痛,常配大黄用,如栀子汤《圣济总录》。
虎杖含有蓼甙、有机酸、葡萄糖甙、多糖类等。有清热解毒、清凉解暑、健胃清食作用,是一种蓼科植物。清热解毒,利胆退黄,祛风利湿,散瘀定痛,止咳化痰。用于关节痹痛,湿热黄疸,经闭,产后瘀血不下,癓瘕,咳嗽痰多,水火烫伤,跌打损伤,痈肿疮毒。
紫花地丁,别名铧头草、光瓣堇菜、犁头草。拉丁文名Viola philippica Car.紫花地丁味苦、微辛,性寒;归心、肝经;气微散泄,具有清热解毒,凉血消肿的功效。主治疔疮痈肿、痄腮,瘰疬,丹毒,乳痈,肠痈,湿热与泻痢,黄疸,目赤肿痛,喉痹,毒蛇咬伤。
谷精草拉丁学名:Eriocaulon buergerianum辛甘,凉;祛风散热,明目退翳。主治治目翳,雀盲,头痛,齿痛,喉痹,鼻衄。风热目赤肿痛、羞明、眼生翳膜。本品轻浮升散,善疏散头面风热、明目退翳,用治风热上攻所致目赤肿痛、羞明多泪、眼生翳膜者,可与荆芥、决明子、龙胆草等配伍,如谷精草汤。《开宝本草》:“主疗喉痹,齿风痛及诸疮疥。”《本草纲目》:“谷精草体轻性浮,能上行阳明分野。凡治目中诸病,加而用之,甚良。明目退翳之功,似在菊花之上也。”
具体实施例1:
每年4~6月在桑葚果实成熟时采收,洗净,去杂质,晒干或略蒸后晒干。
再将其余原料女贞子,谷精草,郁金,丹参,茯苓,金盏花,茵陈,天花粉,桑寄生,白芍,栀子,虎杖,紫花地丁,山茱萸;粉碎,提取制成膏剂、颗粒剂或粉剂。
将制备好的桑葚与提取物混合,紫外线杀菌消毒装袋。
具体实施例2:
每年4~6月在桑葚果实成熟时采收,洗净,去杂质,晒干或略蒸后晒干。大约5000g;再取其他原料女贞子1500g,谷精草1500g,郁金1500g,丹参1500g,茯苓1500g,金盏花1500g,茵陈1500g,天花粉1500g,桑寄生1500g,白芍1500g,栀子1500g,虎杖1500g,紫花地丁1500g,山茱萸1500g;洗净晾干,用粉碎机粉碎过80-100目筛;将过筛的颗粒物浸泡水中12小时,然后放入提取罐加热煮沸1小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸半小时,过滤,加热浓缩至膏状,静置备用。将膏状提取物置于70-90%乙醇中浸泡1-2小时,在水浴锅内加热到60℃-70℃,浸提2h,每10min搅拌一次,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状滤液,再置入双效真空浓缩器中,浓缩后的膏剂加蜂蜜调和制成颗粒剂;或直接干燥制成粉剂。然后加蜂蜜调和,制成颗粒剂,混合制备好的桑葚,紫外线灭菌,包装即得;使用时直接开水冲泡。
具体实施例3:
每年4~6月在桑葚果实成熟时采收,洗净,去杂质,晒干或略蒸后晒干。大约3000g;再取其他原料女贞子1000g,谷精草1000g,郁金1000g,丹参1000g,茯苓1000g,金盏花1000g,茵陈1000g,天花粉1000g,桑寄生1000g,白芍1000g,栀子1000g,虎杖1000g,紫花地丁1000g,山茱萸1000g;将其余原料组份放入10倍量乙醇中,加热回流提取2次,每次1~2小时,将2次提取液合并静置;再将上述乙醇提取过的其余原料药材的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述两种提取液合并,减压浓缩相对密度为1.35(80℃)的滤液,回收乙醇,将所得滤液调整比重到1.06,减压得浸膏,然后加蜂蜜调和,放入制粒机中制成1-2厘米颗粒剂,浓缩成糊状,或直接干燥制成粉剂。混合制备的桑葚,紫外线灭菌,包装即得。
具体实施例4:
每年4~6月在桑葚果实成熟时采收,洗净,去杂质,晒干或略蒸后晒干。大约3500g,再取其他原料女贞子1100g,谷精草1200g,郁金1100g,丹参1300g,茯苓1200g,金盏花1200g,茵陈1100g,天花粉1200g,桑寄生1200g,白芍1000g,栀子1200g,虎杖1200g,紫花地丁1100g,山茱萸1100g;取其他原料洗净去杂,泡入乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液;所述步骤b中,将上述步骤提取的提取液放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06的浓缩液;将上述步骤得到的浸膏置入双效真空浓缩器中,浓缩至90℃时相对密度为1.50的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量;浓缩成的膏剂。混合制备好的桑葚,紫外线灭菌,包装即得;使用时直接开水冲泡。
药理学试验
急性毒性实验
一、试验材料:
动物:昆明种小鼠,体重21-24g,雌雄各半,山东大学生物试验室育种。实验物:本发明煎煮液。
二、方法:
1、LD50计算:采用改良寇氏法,将小鼠随机分成5组,每组10只,雌雄各半,将本发明加蒸馏水溶解,配成最大浓度,按小鼠最大允许容量给药,所给剂量按生药量依次为18,14.4,11.5,9.2,7.4(g.kg-1),在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml,观察动物死亡情况。
2、最大耐受剂量测定(MTD值):取小鼠20只,雌雄各10只。将本发明加蒸馏水溶解,配成最高浓度,按动物的最大耐受量,以注射灌喂器能抽动为准。在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml(每ml含生药0.36g),总药量为18g生药/kg.d,相当临床成人50Kg体重用量的300倍。给药后连续观察7天。
三、试验结果:
在LD50计算中当用最大允许浓度和最大允许容量给予小鼠时(18g/Kg.d),未见小鼠死亡,即未测出LD50,只可求最大耐受剂量,在7天观察期中,动物其食欲、活动、毛色、精神状态等皆正常,发育正常,未见有死亡。即选用相当于临床剂量的300倍药量,并无不良反应发生,表明急性毒性极小,MTD>18g/Kg.d。
实验例2:长期毒性实验资料
本发明的煎煮剂经灌胃给药6个月的动物长期毒性试验结果:SD大鼠分成三组,每组30只,雌雄各半(分成高、中、低三个剂量组,每组10只),其中第一组经灌胃给生理盐水;第二组经灌胃给本发明的剂量为0.25g、2.5g和12.5g/kg.d;第三组经灌胃给洛伐他汀的剂量为0.5mg、5.0mg和50.0mg/kg.d。在给药期间,分别观察各组动物给药后的临床表现、血液学、血生化、脏器系数和组织病理学等指标进行药物毒性的评价。研究结果:主要毒性反应表现在洛伐他汀50mg/kg.d和5.0mg组,表现在给药后SD大鼠出现了流涎、毛蓬松、忙碌、腹泻、踏脚等反应和症状,总摄食量和体重减轻;血液检查显示白细胞总数有所增加,红细胞总数、血红蛋白含量和血小板计数明显下降(P均<0.05);血液生化检查显示ALT、AST、ALP和CK升高1~8倍(P均<0.05),肌酐和尿素氮有所升高(P均<0.05),但未引起动物死亡;组织病理学分析结果显示洛伐他汀50mg/kg.d组出现了与人相似的肝肾病理改变。而生理盐水组和本发明0.25g、2.5g和12.5g/kg.d三个剂量组和洛伐他汀0.5mg/kg.d剂量组在整个给药期间均未出现类似反应,在恢复期观察期间,出现反应的各组动物的症状逐渐消失恢复正常状态。可见本发明不但能够降低洛伐他汀的毒副作用,而且可使洛伐他汀的临床无毒剂量增加至5~25倍(P均<0.01)。
试验例3:累积毒性实验:
本发明煎煮剂对小鼠按7.69、19.18和43.21g生药/kg连续用药15周(1.0ml/100g体重,每天2次)及停药3周后,结果表明:本发明中药制剂对大鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药15周及停药3周后,大鼠各脏器均无明显改变。说明本发明中药制剂内服胶囊剂对大鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
药理学实验说明:
1实验材料
1.1药品
本发明清肝明目的桑葚茶(用实施例2的方法制备);阳性对照药:杞菊地黄丸,同仁堂出品,市售。
1.2动物Wistar大鼠,昆明种小鼠,♀♂均用。
2对肝损伤小鼠血清中ALT、ET、NO含量的影响
2.1分组:取90只昆明小鼠随机分为6组,每组15只,A组为正常对照组;B组为模型对照组;C组为阳性对照组;D1组为本发明低剂量组,D2组为本发明中剂量组,D3组为本发明高剂量组;
2.2造模方法:采用卡介苗和脂多糖联合的方法建立免疫性肝损伤小鼠模型。各组动物适应性喂养3d后,除正常对照组外,每只小鼠1次尾静脉注射卡介苗5×107个活菌,于注射BCG后第12d静脉注射脂多糖7.5μg/鼠,于16h后处死取材,正常对照组2次都以相同方法注射等量生理盐水。
2.3给药与处理:静脉注射卡介苗的第一天起开始灌胃给药,1次/d。正常对照组与模型对照组:生理盐水灌胃,灌胃量同药物治疗组的用药容量;阳性对照药物治疗组:杞菊地黄丸,5.9g/kg剂量给药;本发明组低3.9g/kg、中7.8g/kg、高11.7g/kg剂量给药。正常对照组于第12d注射生理盐水后16h,眼球后静脉丛取血,并处死动物取肝组织送检;其余组于静脉注射脂多糖后16h,眼球后静脉丛取血,并处死动物取肝组织送检。
2.4观察指标及检测方法:①检测谷-丙转氨酶(ALT):采用化学比色法测定。②内源性一氧化氮(N0)测定:采用放射免疫法,剖取0.5g肝脏制成10%肝组织匀浆,在4℃条件下,3000转/min,离心10min,取上清液。③内皮素(ET)检测:采用放射免法直接测定血浆ET浓度。
表1各组血清ALT、ET、N0的变化情况比较
*与模型组比较,*P<0.05、**P<0.01;Δ与阳性对照组比较,ΔP<0.05。
3、对慢性肝损伤的保护作用
取40只昆明小鼠随机分为4组,每组10只,大鼠皮下注射10%5ml/kg四氯化碳油溶液,每周2次,连续注射3个月,造成四氯化碳慢性肝损伤动物模型,观察本发明药物对损伤肝的保护作用。
正常对照组(A)与模型对照组(B):生理盐水灌胃,灌胃量同药物治疗组的用药容量;阳性对照药物治疗组(C):杞菊地黄丸,2.7g/kg剂量给药;本发明(D),2.7g/kg剂量给药。正常对照组于第12d注射生理盐水后16h,眼球后静脉丛取血,并处死动物取肝组织送检;其余组于静脉注射脂多糖后16h,眼球后静脉丛取血,并处死动物取肝组织送检。
表2本发明药物对慢性肝损伤大鼠的保护作用(X±SD)
*与模型组比较,*P<0.05、**P<0.01;Δ与阳性对照组比较,ΔP<0.05。
从以上结果可以看出,检测合格的本发明药物对肝损伤小鼠血清中ALT、ET、N0含量有显著性改善,并且对慢性肝损伤有明显的的保护作用,与阳性对照药物比较有显著性差异。
临床试验:
一、实验对象:采用本发明桑葚保健茶共在80例患者实验,都是经常玩电脑游戏、手机游戏者。其中男40例,女40例;年龄最大者55岁,年龄最小者20岁。大部分病患均为白领,学生、机关干部;自述都有视物模糊、夜盲;失眠健忘、肝阴亏损,两目干涩、视力减退;肝火上炎,目赤肿痛;经常玩电脑游戏、手机游戏;眼睛发干发涩,熬夜,饮酒应酬;且面色晦暗,女病患大都有月经不调,面上起痘,色斑严重。实验组、对照组均40人,病症相同或类似,对照组采用市售清肝明目眼药水+杞菊地黄丸调理。
治疗方法:
用法用量:治疗组采用本发明桑葚保健茶。方用:桑葚30g,女贞子12g,谷精草13g,郁金12g,丹参13g,茯苓11g,金盏花12g,茵陈13g,天花粉13g,桑寄生12g,白芍13g,栀子12g,虎杖12g,紫花地丁13g,山茱萸13g;其用法与用量如下:每天3袋,,每袋冲泡三次为限。疗程:一个月为限。对照组每日服用中药成药(杞菊地黄丸)加滴眼药水(珍珠明目滴眼液,市售),一个月为限。
疗效评价标准
治愈:以上症状体征完全改善,患者无任何不良感觉,心情舒畅,精神焕发,眼睛不再发干发涩,视线模糊,面部色斑减少;显效:体征显著改善,患者基本无不良感觉,心情舒畅,精神很好。有效:体征明显改变,偶感稍有不适,但能接受,心情较好,精力比较充沛。无效:体征无任何改变,症状如前,心情抑郁,精神萎靡不振。面色晦暗,眼睛还是发干发涩。
结果见表1两组疗效比较(%)
| 组别 | 人数 | 痊愈 | 好转 | 有效 | 无效 | 总有效率 |
| 治疗组 | 40 | 33(82.5) | 5(12.5) | 1(2.5) | 1(2.5) | 97.5 |
| 对照组 | 40 | 22(55) | 8(20) | 6(15) | 4(10) | 90 |
讨论:本发明的治疗组效果明显高于对照组。表明本发明保健茶饮代替中药完全可行。本发明的优点是,作为日常饮用,能改善口感,也让人不产生厌恶心理,对中药气味不再排斥。
针对都市上班族普遍使用电脑办公久视,爱打游戏学生、烟酒无度,夜生活不节制、过度用眼总得不到缓解等伤害肝脏的行为,采用补虚益精气,祛风明目,滋补肝肾的中药配伍,并且解决了中药口感不佳,不能长期服用的缺点。《黄帝内经》的“五劳所伤”中有一伤:“久视伤血“。这里的血,指的就是肝血。眼睛与肝脏联系紧密。肝藏血,即肝脏具有贮藏血液和调节血量的功能,而且肝开窍于目。双眼受到血的给养才能视物,而过度用眼,会使肝血亏虚,使双目得不到营养的供给,从而出现眼干涩、看东西模糊、夜盲等。另外,长期久坐用眼,除双目供血不足外,颈椎、腰椎也会产生劳损,总得不到缓解,也会对肝脏造成损害。这种情况下,出现双眼疲劳、视力下降,甚至面色萎黄,头晕眼花的症状,也就不奇怪了。久视以及辐射,为电脑一族的眼睛健康埋下了隐患。
中国传统医学认为桑椹味酸,性微寒,具有提高人体免疫力、补血滋阴、生津止渴、润肠祛燥等功效,主治阴血不足而致的头晕目眩、耳鸣心悸、烦躁失眠、腰膝酸软、须发早白、消渴止干、大便干结、滋阴补血、安神补脑、利关节、去风湿、解酒等功效。再加上一些滋肝补肾、清肝明目,口感清淡的中药,共同作用,对肝阴亏损,两目干涩、视力减退;肝火上炎,目赤肿痛;对用眼过度造成眼睛发干发涩有良好的保健作用。
Claims (10)
1.一种桑葚清肝明目保健茶,其特征在于,所述桑葚清肝明目保健茶中各种原料的重量份数包括:桑葚10~50份,女贞子10~20份,谷精草10~20份,郁金10~20份,丹参10~20份,茯苓10~20份,金盏花10~20份,茵陈10~20份,天花粉10~20份,桑寄生10~20份,白芍10~20份,栀子10~20份,虎杖10~20份,紫花地丁10~20份,山茱萸10~20份。
2.根据权利要求1所述桑葚清肝明目保健茶,其特征在于,所述桑葚清肝明目保健茶中各种原料的重量份数包括:桑葚10~30份,女贞子10~15份,谷精草10~15份,郁金10~15份,丹参10~15份,茯苓10~15份,金盏花10~15份,茵陈10~15份,天花粉10~20份,桑寄生10~20份,白芍10~20份,栀子10~20份,虎杖10~20份,紫花地丁10~20份,山茱萸10~20份。
3.根据权利要求1所述桑葚清肝明目保健茶,其特征在于,所述桑葚清肝明目保健茶中各种原料的重量份数包括:桑葚10~40份,女贞子10~20份,谷精草10~20份,郁金10~20份,丹参10~20份,茯苓10~20份,金盏花10~20份,茵陈10~20份,天花粉10~15份,桑寄生10~15份,白芍10~15份,栀子10~15份,虎杖10~15份,紫花地丁10~15份,山茱萸10~15份。
4.一种如权利要求1~3项任一项所述桑葚清肝明目保健茶的制备方法,其特征在于,所述桑葚清肝明目保健茶的制备步骤包括以下方面:
a.桑葚的制备;
b.将所述其他原料粉碎、浸泡、加热、回流提取2次;
c.再将其他原料提取的药液放入浓缩器中浓缩;加蜂蜜或糊精制成颗粒剂、粉剂或膏剂;
d.将浓缩的颗粒剂、粉剂或膏剂与制备好的桑葚混合,制备成保健茶。
5.根据权利要求4所述桑葚清肝明目保健茶的制备方法,其特征在于,所述步骤a中,每年4~6月桑葚果实成熟时采收,洗净,去杂质,晒干或略蒸后晒干。
6.根据权利要求4所述桑葚清肝明目保健茶的制备方法,其特征在于,所述步骤b中,取其他原料洗净晾干,用粉碎机粉碎过80-100目筛;将过筛的颗粒物浸泡水中12小时,然后放入提取罐加热煮沸1小时,过滤,滤液备用;滤渣加水,第二次加热,煮沸45分钟,过滤,滤液备用;滤渣再加水,第三次加热煮沸半小时,过滤,加热浓缩至膏状,静置备用。
7.根据权利要求4所述桑葚清肝明目保健茶的制备方法,其特征在于,所述步骤c中,将膏状提取物置于70-90%乙醇中浸泡1-2小时,在水浴锅内加热到60℃-70℃,浸提2h,每10min搅拌一次,用纱布过滤,残渣中加入50-60%乙醇,60℃-70℃继续浸提2h,每10min搅拌一次,纱布过滤,合并浸提液,浓缩成糊状滤液,再置入双效真空浓缩器中,浓缩后的膏剂加蜂蜜调和制成颗粒剂;或直接干燥制成粉剂。
8.根据权利要求4所述桑葚清肝明目保健茶的制备方法,其特征在于,所述步骤d中,将制好的桑葚与提取的颗粒剂、粉剂或膏剂混合,经紫外线消毒杀菌后装袋,使用时直接冲水泡饮。
9.一种根据如权利要求1~3项任一项所述桑葚清肝明目保健茶的制备方法,其特征在于,所述保健茶的其他原料制成膏剂时步骤还可以为:
a、取其他原料放入乙醇中浸泡,热提取2次;
b、将提取液放置于浓缩器中浓缩成膏剂。
10.根据权利要求9中所述桑葚清肝明目保健茶的制备方法,其特征在于,其他原料制成膏剂时,所述步骤a中,取其他原料洗净去杂,泡入乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液;所述步骤b中,将上述步骤提取的提取液放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06的浓缩液;将上述步骤得到的浸膏置入双效真空浓缩器中,浓缩至90℃时相对密度为1.50的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量;浓缩成的膏剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410669094.1A CN104365942A (zh) | 2014-11-20 | 2014-11-20 | 一种桑葚清肝明目保健茶及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410669094.1A CN104365942A (zh) | 2014-11-20 | 2014-11-20 | 一种桑葚清肝明目保健茶及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104365942A true CN104365942A (zh) | 2015-02-25 |
Family
ID=52545333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410669094.1A Pending CN104365942A (zh) | 2014-11-20 | 2014-11-20 | 一种桑葚清肝明目保健茶及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104365942A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104958445A (zh) * | 2015-07-14 | 2015-10-07 | 青岛恒波仪器有限公司 | 一种防治风热上攻目赤肿痛的蔓荆子口服液及其制备方法 |
| CN105166237A (zh) * | 2015-10-12 | 2015-12-23 | 青岛恒波仪器有限公司 | 一种护肝养肝丹参叶保健茶及其制备方法 |
| CN105233034A (zh) * | 2015-10-23 | 2016-01-13 | 李有花 | 治疗耳鸣的清肝利胆制剂及制备方法 |
| CN105343516A (zh) * | 2015-11-09 | 2016-02-24 | 青岛安倍康生物医药技术有限公司 | 一种治疗肝火上炎的夏枯草口服液及其制备方法 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1676009A (zh) * | 2004-03-30 | 2005-10-05 | 陈仲亮 | 一种杞菊明目茶 |
| CN102366009A (zh) * | 2011-06-22 | 2012-03-07 | 王学文 | 清热明目养生茶 |
| CN103007035A (zh) * | 2012-12-27 | 2013-04-03 | 青岛华仁信息技术开发有限公司 | 一种清肝明目的枸杞叶中药茶饮及其制备方法 |
| CN103202368A (zh) * | 2013-03-22 | 2013-07-17 | 安徽华佗国药股份有限公司 | 一种平肝明目茶及其制备方法 |
| CN103719492A (zh) * | 2013-12-31 | 2014-04-16 | 青岛恒波仪器有限公司 | 一种绞股蓝护肝养肝保健茶及其制备方法 |
| CN103719498A (zh) * | 2013-12-31 | 2014-04-16 | 青岛恒波仪器有限公司 | 一种提高免疫力的黄精保健茶及其制备方法 |
| CN103749823A (zh) * | 2013-12-31 | 2014-04-30 | 青岛恒波仪器有限公司 | 一种滋肝明目的女贞子保健茶及其制备方法 |
| CN103749819A (zh) * | 2013-12-31 | 2014-04-30 | 青岛恒波仪器有限公司 | 一种降糖降脂的山茱萸保健茶及其制备方法 |
| CN104146105A (zh) * | 2014-08-29 | 2014-11-19 | 龚俊豪 | 一种健脾、补肾、活血、养肝明目的保健茶及其制备方法 |
-
2014
- 2014-11-20 CN CN201410669094.1A patent/CN104365942A/zh active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1676009A (zh) * | 2004-03-30 | 2005-10-05 | 陈仲亮 | 一种杞菊明目茶 |
| CN102366009A (zh) * | 2011-06-22 | 2012-03-07 | 王学文 | 清热明目养生茶 |
| CN103007035A (zh) * | 2012-12-27 | 2013-04-03 | 青岛华仁信息技术开发有限公司 | 一种清肝明目的枸杞叶中药茶饮及其制备方法 |
| CN103202368A (zh) * | 2013-03-22 | 2013-07-17 | 安徽华佗国药股份有限公司 | 一种平肝明目茶及其制备方法 |
| CN103719492A (zh) * | 2013-12-31 | 2014-04-16 | 青岛恒波仪器有限公司 | 一种绞股蓝护肝养肝保健茶及其制备方法 |
| CN103719498A (zh) * | 2013-12-31 | 2014-04-16 | 青岛恒波仪器有限公司 | 一种提高免疫力的黄精保健茶及其制备方法 |
| CN103749823A (zh) * | 2013-12-31 | 2014-04-30 | 青岛恒波仪器有限公司 | 一种滋肝明目的女贞子保健茶及其制备方法 |
| CN103749819A (zh) * | 2013-12-31 | 2014-04-30 | 青岛恒波仪器有限公司 | 一种降糖降脂的山茱萸保健茶及其制备方法 |
| CN104146105A (zh) * | 2014-08-29 | 2014-11-19 | 龚俊豪 | 一种健脾、补肾、活血、养肝明目的保健茶及其制备方法 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104958445A (zh) * | 2015-07-14 | 2015-10-07 | 青岛恒波仪器有限公司 | 一种防治风热上攻目赤肿痛的蔓荆子口服液及其制备方法 |
| CN105166237A (zh) * | 2015-10-12 | 2015-12-23 | 青岛恒波仪器有限公司 | 一种护肝养肝丹参叶保健茶及其制备方法 |
| CN105233034A (zh) * | 2015-10-23 | 2016-01-13 | 李有花 | 治疗耳鸣的清肝利胆制剂及制备方法 |
| CN105343516A (zh) * | 2015-11-09 | 2016-02-24 | 青岛安倍康生物医药技术有限公司 | 一种治疗肝火上炎的夏枯草口服液及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105727032A (zh) | 一种平肝明目的保健饮料及其制备方法 | |
| CN104398986A (zh) | 一种安神补脑的淫羊藿口服液及其制备方法 | |
| CN105496917A (zh) | 一种积雪草抗皱面霜及其制备方法 | |
| CN103735835B (zh) | 一种治疗少白头的中药制剂及其制备方法 | |
| CN105267477A (zh) | 一种清肝明目的丹参叶保健茶及其制备方法 | |
| CN104206594A (zh) | 一种降压降脂的桑寄生保健茶及其制备方法 | |
| CN104365942A (zh) | 一种桑葚清肝明目保健茶及其制备方法 | |
| CN104958445A (zh) | 一种防治风热上攻目赤肿痛的蔓荆子口服液及其制备方法 | |
| CN103749825B (zh) | 一种乌发明目、祛斑的女贞子美容茶及其制备方法 | |
| CN105831543A (zh) | 一种平肝明目的菊花保健饮料及其制备方法 | |
| CN103783508B (zh) | 一种苦荞美容祛斑口服液及其制备方法 | |
| CN105125946A (zh) | 一种清心除烦的栀子口服液及其制备方法 | |
| CN104304595A (zh) | 一种清肝明目的菟丝子保健茶及其制备方法 | |
| CN103749820B (zh) | 一种清肝明目的炒青葙子茶及其制备方法 | |
| CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
| CN104473153B (zh) | 一种美容养颜的桑葚口服液及其制备方法 | |
| CN105455125A (zh) | 一种提高免疫力的龙眼肉口服液及其制备方法 | |
| CN105166237A (zh) | 一种护肝养肝丹参叶保健茶及其制备方法 | |
| CN105233052A (zh) | 一种治疗轻度脂肪肝的中药制剂及其制备方法 | |
| CN105343593A (zh) | 一种降压降脂的夏枯草保健口服液及其制备方法 | |
| CN104888158A (zh) | 一种提高免疫力的罗布麻叶口服液及其制备方法 | |
| CN104286864A (zh) | 一种提高免疫力的沙苑子口服液及其制备方法 | |
| CN104324329A (zh) | 一种安神补脑的桑葚口服液及其制备方法 | |
| CN105211441A (zh) | 一种降压降脂的丹参叶保健茶及其制备方法 | |
| CN104397282A (zh) | 一种安神补脑的刺五加保健茶及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150225 |
|
| RJ01 | Rejection of invention patent application after publication |